Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzomenib in Metastatic Castration-Resistant Prostate Cancer
NCT07914855Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2027
- Primary completion
- Jan 2029
01
Overview
A Phase 2 trial of enzomenib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
enzomenib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07914855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914855.